We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the agreement, Eris will take over the marketing and distribution rights for more than 130 products across multiple therapeutic areas owned by the generics business.
Strides Shasun and Eris Lifesciences have entered into definitive agreements for sale of Strides’ India branded generics business to Eris for an aggregate cash consideration of Rs 500 crores.